These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17519820)

  • 1. [Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)].
    Gervais R; Le Guen Y; Le Caer H; Paillotin D; Chouaid C;
    Rev Mal Respir; 2007 May; 24(5):653-8. PubMed ID: 17519820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Full chemotherapy in elderly patients with small cell bronchial carcinoma.
    Nõu E
    Acta Oncol; 1996; 35(4):399-406. PubMed ID: 8695151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
    Gervais R; Le Caer H; Monnet I; Falchero L; Baize N; Olivero G; Thomas P; Berard H; Auliac JB; Chouaid C;
    Clin Lung Cancer; 2015 Mar; 16(2):100-5. PubMed ID: 25467927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide-cisplatin and thoracic radiation therapy salvage of incomplete responders to a noncisplatin induction regimen for limited and extensive small-cell carcinoma of the lung.
    Shaw EG; Frytak S; Eagan RT; Richardson RL; Creagan ET; Jett JR; Foote RL; Su JQ; Schaid DJ; Lee RE
    Am J Clin Oncol; 1996 Apr; 19(2):154-8. PubMed ID: 8610640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
    Lebeau B; Chouaïd C; Baud M; Masanès MJ; Febvre M
    Lung Cancer; 2010 Feb; 67(2):188-93. PubMed ID: 19394109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality versus quantity of life in the treatment of patients with advanced small-cell lung cancer? A randomized phase III comparison of weekly carboplatin and teniposide versus cisplatin, adriamycin, etoposide alternating with cyclophosphamide, methotrexate, vincristine and lomustine. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Alberto P; Hürny C; Bacchi M; Leyvraz S; Thürlimann B; Cerny T; Martinelli G; Stahel R; Ludwig C
    Ann Oncol; 1995 Jan; 6(1):41-8. PubMed ID: 7536028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
    Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA; Bacchi M; Hürny C; Bernhard J; Cerny T; Martinelli G; Leyvraz S; Senn HJ; Stahel R; Siegenthaler P
    Ann Oncol; 1995 Feb; 6(2):157-66. PubMed ID: 7786823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term results of surgery and chemotherapy in small cell lung cancer.
    Rea F; Callegaro D; Favaretto A; Loy M; Paccagnella A; Fantoni U; Festi G; Sartori F
    Eur J Cardiothorac Surg; 1998 Oct; 14(4):398-402. PubMed ID: 9845145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolution of superior vena cava obstruction in small cell lung cancer patients treated with chemotherapy.
    Tan EH; Ang PT
    Ann Acad Med Singap; 1995 Nov; 24(6):812-5. PubMed ID: 8838986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Reye syndrome in a child having received chemotherapy].
    Dubern B; Alessandri JL; Montbrun A; Attali T; Pilorget H; Samperiz S
    Arch Pediatr; 1998 Mar; 5(3):342-3. PubMed ID: 10328010
    [No Abstract]   [Full Text] [Related]  

  • 13. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.
    Newlands ES; Mulholland PJ; Holden L; Seckl MJ; Rustin GJ
    J Clin Oncol; 2000 Feb; 18(4):854-9. PubMed ID: 10673528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etoposide (VP-16) containing combination chemotherapy for treatment of patients with small cell lung cancer.
    Behera D; Jindal SK; Sharma SC
    Indian J Chest Dis Allied Sci; 1995; 37(1):15-9. PubMed ID: 16892733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.
    Osterlind K; Hansen M; Hirsch FR; Dombernowsky P; Sörenson S; Pedersen AG; Hansen HH
    Ann Oncol; 1991 Jan; 2(1):41-6. PubMed ID: 1848996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.